Petrushenko V. V., Grebeniuk D. I., Gladkykh V. Y.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Abstract. Improving the functional state of the liver and reducing the rate of disease progression are key objectives in the treatment of patients with esophageal and gastric variceal bleeding. The aim of the study was to evaluate the effectiveness of a prolonged regimen of phosphatidylcholine administration in the complex treatment of liver cirrhosis complicated by esophageal and gastric variceal bleeding. The prospective study included 62 patients who were randomly divided into two groups. The experimental group (32 patients) consisted of patients who were prescribed a prolonged regimen of phosphatidylcholine to maintain liver function. The comparison group (30 patients) included patients who did not receive these drugs. To assess the dynamics of changes in the functional state of the liver, we analyzed the following indices: total bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltranspeptidase, alkaline phosphatase, albumin, prothrombin index. The length of hospital stay was significantly shorter in the experimental group (8.4±2.6 days) than in the comparison group (10.3±2.3 days). Patients in the experimental group had a tendency to faster progressive decrease in the intensity of the studied indices, compared with patients in the comparison group. Improvement in the functional state of the liver was also observed after discharge of patients from the experimental group from the hospital. In the comparison group, there was a slight improvement in laboratory parameters of liver function during the hospital stay. After discharge from the hospital and cessation of intensive care, no changes in laboratory indices were observed. The use of a prolonged regimen of phosphatidylcholine in the complex treatment of patients with liver cirrhosis complicated by esophageal and gastric variceal bleeding can significantly improve the basic clinical and laboratory parameters of liver function and reduce hospital stay. In the future it is planned to study the functional state of the liver in the dynamics at 6 and 12 months.

phosphatidylcholine, liver cirrhosis, esophageal and gastric variceal bleeding, functional state of the liver.

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736- 1788. doi: 10.1016/S0140-6736(18)32203-7.
2. Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. Wiley Interdiscip Rev SystBiol Med. 2021 Jan;13(1):e1499. doi: 10.1002/wsbm.1499.
3. Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther. 2010 Dec;32(11-12):1343-50. doi: 10.1111/j. 1365-2036.2010.04473.x.
4. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013 Jun;144(7):1426-1437. doi: 10.1053/j.gastro.2013.02.042.
5. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006 Jan;44(1):217-31. doi: 10.1016/j.jhep.2005.10.013.
6. Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: a populationbased cohort study. Liver Int. 2012 Jan;32(1):79-84. doi: 10.1111/j.1478-3231.2011.02517.x.
7. Ge PS, Runyon BA. Treatment of Patients with Cirrhosis. N Engl J Med. 2016 Aug 25;375(8):767-77. doi: 10.1056/NEJMra1504367.
8. Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol. 2020 Mar 26;7(1):e000368. doi: 10.1136/bmjgast-2019-000368.
9. Chen M, Huang H, Zhou P, Zhang J, Dai Y, Yang D, et al. Oral Phosphatidylcholine Improves Intestinal Barrier Function in Drug-Induced Liver Injury in Rats. Gastroenterol Res Pract. 2019 Sep 2;2019:8723460. doi: 10.1155/2019/8723460.
10. Gundermann KJ, Kuenker A, Kuntz E, Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643-59. doi: 10.1016/s1734-1140(11)70576-x.

«Bulletin of problems biology and medicine» Issue 2 (160), 2021 year, 119-122 pages, index UDK 616.149 – 008.341.1:347.440.32

10.29254/2077-4214-2021-2-160-119-122